Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

Role of GLP-1 Analogues in Cardiovascular Disease Management

Cardiovascular Benefits of GLP-1 Receptor Agonists

  • The American College of Cardiology recommends GLP-1 receptor agonists to reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus and established cardiovascular disease, with semaglutide and liraglutide demonstrating the strongest evidence for cardiovascular benefit 1, 2
  • GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or stroke, in patients with type 2 diabetes mellitus and established cardiovascular disease 2, 3
  • Liraglutide reduced the primary composite outcome of cardiovascular death, non-fatal myocardial infarction, or stroke by 13% in the LEADER trial 1
  • Semaglutide reduced the primary composite outcome by 26% in the SUSTAIN-6 trial 1
  • In non-diabetic patients with pre-existing cardiovascular disease and BMI >27, semaglutide 2.4 mg weekly reduced cardiovascular endpoints by 20% compared to placebo 1
  • The FDA approves liraglutide to reduce the risk of MACE in adults with type 2 diabetes and established cardiovascular disease 3

Clinical Application Guidelines

  • The American Diabetes Association recommends considering GLP-1 receptor agonists as first-line therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease 7
  • GLP-1 receptor agonists can be considered in patients without established ASCVD but with specific high-risk indicators, including age ≥55 years with coronary, carotid, or lower extremity artery stenosis >50% 7
  • The decision to use GLP-1 receptor agonists for cardiovascular risk reduction should be considered independently of baseline HbA1c or individualized HbA1c targets 7

Comparative Effectiveness with Other Agents

  • For patients with heart failure, particularly heart failure with reduced ejection fraction, SGLT2 inhibitors have stronger evidence for benefit than GLP-1 receptor agonists 5, 7
  • For patients where atherosclerotic cardiovascular disease is the primary concern, GLP-1 receptor agonists have the strongest evidence for MACE reduction 7

Safety Considerations and Adverse Effects

  • Gastrointestinal effects are the most common adverse effects of GLP-1 receptor agonists, including nausea and vomiting, dyspepsia, diarrhea, gastrointestinal reflux, and constipation 1, 6
  • Cardiac arrhythmia/tachycardia may occur with GLP-1 receptor agonist use, and patients should be monitored and considered for beta-blockers if symptomatic 1, 7
  • Acute pancreatitis is a rare adverse effect of GLP-1 receptor agonists, and they should be used with caution in patients with a history of pancreatitis 1

Perioperative Considerations

  • GLP-1 receptor agonists may delay gastric emptying, potentially increasing the risk of regurgitation and pulmonary aspiration 8
  • Some studies suggest an association between perioperative GLP-1 receptor agonist use and increased risk of pulmonary aspiration 8

REFERENCES